Articles On Race Oncology (ASX:RAC)

Racura and Purdue University in US partner for molecular level studies on how (E,E)-bisantrene binds to the MYC-G4 DNA structure Collaborative preclinical program led by Professor Danzhou Yang, an internationally recognised expert Racura t...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

MineLife’s Gavin Wendt backs oil and gas, WA gold and battery-grade manganese plays Rough start, midweek charge, then oil knocks the ASX off its line Silica, lithium and biotech names find another gear in small-cap ranks   Stockhead’s end...

ASX health sector falls 1.85% for the past five days while broader market down  Racura Oncology soars as third and final patient dosed in CPACS Phase I trial  Telix submits new drug application to US FDA for brain cancer imaging agent TLX1...

ASX plunges 1.65%, erasing the week’s gains and then some Hard hits in gold stocks, but broad pullback with eight sectors lower Energy stocks catch a tailwind as crude prices spike   Oil surges as Iran hits Qatar’s LNG operations again Qa...

Final patient in first cohort dosed with RC220 in cardioprotection and anticancer synergy Phase I trial in advanced solid tumours Patient treated by principal investigator Dr Roland Ching-Yu Leung and his team at Queen Mary Hospital in Hon...

Racura is well out in front on the Australian bourse topic-wise today – and has had the single biggest jump price-wise – even under what has been a brutal Thursday selling day, though it’s followed closely by another healthcare company (a w...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and sinking deep into the red. At the time of writing, the benchmark index is down 1.5% to 8,508.3 points. Four ASX shares that are not letting that hold them back are...

Shares in Racura Oncology Ltd (ASX: RAC) have jumped more than 10% in early trade after the company announced the successful first dosing of a patient in Hong Kong with its RC220 cancer compound. The company said in a statement to the A...

ASX rises 0.36% after falling into negative territory just before the RBA decision RBA votes to rase cash rate to 4.1% in 5v4 split decision Real estate and gold stocks lead gains RBA hikes rates in split decision The Reserve Bank did exa...

ASX casts defensive sectors in leading roles Oil keeps the spotlight while gold loses some shine CBA and ANZ deliver supporting performances on rate-hike expectations   The plot thickens for global markets While the Oscars played out in H...

Governance approval secured from Monash Health for Racura’s phase I HARNESS-1 trial of RC220 in EGFR-mutated non-small cell lung cancer Study to test RC220 alongside standard-of-care osimertinib to prevent or delay treatment resistance Fou...

Energy, materials, and health care are all getting a run at the top of the HotCopper forums, with each of the top three managing to stay above what was a pretty red open Monday (though it’s mellowed slightly to lunchtime). Listen to the...

Stockhead’s Tylah Tully previews the 2026 ahead for Racura Oncology (ASX:RAC) and recaps the goals the company achieved throughout 2025. Tune in to hear all the details.   This video was developed in collaboration with Racura Oncology, a St...

Racura scientists develop novel blood-based test for assessing anthracycline cardioprotection Blood test based on recently identified mechanism of action of (E,E)-bisantrene, the active ingredient in RC220 Test to be used in the RAC-010 tr...

Host Tylah Tully sits down with Racura Oncology (ASX:RAC) executive director Peter Smith who talks through the company’s transformative quarter, marked by major intellectual property, clinical and funding milestones. Smith explains the sign...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

It has been a modest year for the S&P/ASX 200 Index (ASX: XJO) in 2025, with an approximate gain of 6%. ASX materials and defence shares have been a real winner thanks to soaring commodity prices and global defence investment.  O...

With more than seven million users moving through HotCopper forums every year, there’s always bound to be some fireside chats – and some companies and stocks definitely shaped as more discussed than others in CY25. Listen to the HotCoppe...

The Brightstar Resources Ltd (ASX: BTR) share price is under pressure today after the company released an update this morning. At the time of writing, the emerging gold producer's shares are trading at 51 cents, down 9.73%. So,...

Immutep Ltd (ASX: IMM) has reported positive results from a clinical trial of a drug it is developing in a bid to treat autoimmune diseases in a novel fashion. The biotechnology company said in a statement to the ASX on Monday morning t...

It’s been a huge year for Racura Oncology (ASX:RAC), and CY26 only promises to get bigger as the biotech developer leaves behind its “Race Oncology” name and dives into further developments for next-gen cancer drugs. Listen to the HotCop...

Good Afternoon and welcome to HotCopper Highlights wrapping up Week 50 of the year, I’m Jon Davidson. In this segment we go over the stocks you were watching and discussing most this week on Australia’s #1 finance website, let’s get into it...

The ASX lithium share Pilbara Minerals Ltd (ASX: PLS) has had an incredible performance in 2025 to date, rising by around 80%, as the below chart shows. You may be wondering what's predicted for the business in the coming year. PLS Gr...

If you have a high tolerance for risk, then it could be worth checking out the small cap ASX stock in this article. That's because Bell Potter believes the signing of an "impressive deal" could be the catalyst to sending its shares material...

Good Afternoon and Welcome to Market Close for Tuesday of Week 50, I’m Jon Davidson. We got the RBA call today and, well, it was what I said would happen: the RBA has kept rates on hold. But it’s not like I was the only one thinking that. ...

Pilbara Minerals shares have been one of the most prominent lithium stocks on the ASX for years now. The company first started attracting major attention in 2015, when it rose by about 900% at one point. In subsequent years, the gains conti...

Race Oncology (ASX:RAC) has issued news of the completion of its recent A$3.2M placement – something that shareholders on the HotCopper forums typically don’t like, but with the placement raised at a premium to the company’s share price, an...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed Wall Street's lead and dropped into the red. At the time of writing, the benchmark index is down 0.2% to 8,609.6 points. Four ASX shares that are not letting that hold t...

Highlights Race Oncology advances its next cancer study Solis Minerals progresses exploration groundwork Nexus Minerals expands prospects at its gold project Race Oncology, Solis Minerals, and Nexus Minerals each reported importan...

Immutep has struck a global deal to commercialise its novel immuno-oncology asset Broker Morgans values Epiminder shares at $2.33 – almost twice their current value Rhythm gets into the US groove with genetic test deal   Shares in immuno-...

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

Highlights ASX 200 and small caps show steady gains Mining and energy sectors capture attention Key project expansions in Australia and abroad Overview of ASX 200 and Small-Cap Movements The ASX stock market saw modest gains as t...

Highlights International Graphite progresses land acquisition for a commercial graphite micronising plant in Western Australia. Recce Pharmaceuticals gains a key Hong Kong patent, strengthening protection for its anti-infective drug ca...

ASX shrugs off hot CPI read, closes up 0.81% Gold, lithium, rare earths lead resources gains Broad upward momentum across eight sectors   Gold and lithium build momentum Lion Selection Group (ASX:LSX) MD Hedley Widdup predicted Australia...

Race Oncology achieves ethics approval for HARNESS-1 Phase 1a/b trial of RC220 with osimertinib in adults with EGFR-mutant non-small cell lung cancer Ethics approval allows lead clinical site Monash Health to start enrolling patients subje...

Anti-infectives house Firebrick Pharma reveals what shareholders think of the company – warts and all Pot play Vitura blooms in the September quarter Recce claims early victory in war against superbugs   In the spirit of being truthful a...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.6% to 8,590.6 points. Four ASX shares that have failed to follow the market higher today are...

ASX health sector fell 1.8% for the week, while broader market dropped 3.86% in the same period  FDA confirms Animal Rule and PRV potential for Island Pharmaceutical’s Galidesivir in Marburg Clever Culture identifies more than $45 million...

Strong clinical data can help biotechs secure lucrative licensing and partnership deals  Dimerix has four licensing deals for lead drug DMX-200 in rare kidney disease Platinum’s Global Health Sciences Fund manager Dr Bianca Ogden notes se...

Good afternoon and welcome to HotCopper’s Market Close for Tuesday of Week 47, I’m Jon Davidson. After Wall Street posted its worst day in a month overnight, no surprise the ASX followed suit with our tech index down over -6% in the final h...

Host Tylah Tully chats to Race Oncology (ASX:RAC) CEO Dr Daniel Tillett to unpack two major new clinical programs for RC220 in lung cancer and AML. He explains the scientific breakthrough that revealed how RC220 truly works, why its dual an...

ASX resists session lows of -0.53pc to close 0.02pc higher Info tech, energy, real estate lead gains Banks and finance stocks in retreat ASX recovers from session lows The ASX 200 started the day in the red and stayed there until the las...

R220’s unique molecular mechanism of action opens major clinical and commercial opportunities RAC expanding clinical activities to include Acute Myeloid Leukaemia and non-small cell lung cancer trials Continued clinical focus on cardiopro...

Race Oncology (ASX:RAC) has sought to expand the total addressable markets it can reach with its cancer drug RC220, on Monday launching a Phase Three Acute Myeloid Leukemia (AML) trial, “bridging RC110 to RC220 providing a… low-cost pathway...

Two dozen esteemed sector figures recently gathered over lunch to recount their career highs and lows One luminary recalls an uncomfortable close encounter with a drug cartel, while others overcame the impact of academic and corporate frau...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Good Afternoon and welcome to HotCopper Highlights for Week 43, I’m Jon Davidson. In this segment the stocks you were watching and discussing the most this week, let’s get into it starting with the most viewed.  Pilbara Minerals has been...

Orthocell Ltd (ASX: OCC) shares are on course to end the week in the red. In morning trade, the ASX stock is down 7% to $1.33. However, longer term shareholders won't be too downbeat. That's because the regenerative medicine company's share...

ASX closes 0.86% higher to reach a new 100-day high after hitting an intraday record  Australia’s unemployment rate climbs to four-year high of 4.5% in September, up from revised 4.3% in August Rate sensitive sectors including real estate,...